All In MedTech

FDA Clearance Tracker · P240009-S006

Neuroguard IEP® 3-in-1 Carotid Stent, Post-Dilation Balloon System with Integrated Embolic Protection

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 4, 2026

Approved

Time to decision

401 days

Received Sep 29, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P240009-S006
Device name
Neuroguard IEP® 3-in-1 Carotid Stent, Post-Dilation Balloon System with Integrated Embolic Protection
Applicant location
Raleigh, NC
Received
Sep 29, 2025
Decided
Nov 4, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P240009

Device type

Device class
Class III

Every decision under product code NIM

FDA's approval statement

As written in FDA's record.

The Neuroguard IEP Direct 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection used in conjunction with the Neuroguard IEP Embolic Protection System is indicated for improving carotid luminal diameter in subjects at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet the criteria outlined below: • Patients with = 50% symptomatic stenosis of the internal carotid artery (ICA) or common carotid artery (CCA) as determined by angiography, CTA, or duplex ultrasound or patients with = 70% asymptomatic stenosis of the internal carotid artery (ICA) or common carotid artery (CCA) as determined by angiography, CTA, or duplex ultrasound • Patients with a reference vessel diameter of 4.0 - 8.0 mm • At least 5 cm of atherosclerosis free space in the ipsilateral common carotid artery between the sheath insertion site and the proximal edge of the target lesion. This device is also indicated for post-dilation of the stent component with simultaneous capture and removal of embolic material.

Source documents

Other decisions for Contego Medical, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.